alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 27,026–27,050 of 27,380 studies, newest first · page 1082 of 1096.

June 1990 2

  1. 1990-06-01

    Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein

    ✓ Peer-reviewed Risk genes beyond APOE Science (New York, N.Y.)

    Key finding: Platelets stimulated with thrombin or calcium ionophore (A23187) secrete a protein functionally and immunologically identical to the inhibitor, implying a role for this inhibitor in hemostasis. +3 more findings

    Full summary, score breakdown and related studies → Original source

  2. 1990-06-01

    Autoimmune thyroiditis associated with mild "subclinical" hypothyroidism in adults with Down syndrome: a comparison of patients with and without manifestations of Alzheimer disease

    ✓ Peer-reviewed Down syndrome and Alzheimer's American journal of medical genetics

    Key finding: Relative to control individuals, DS patients had, overall, lower mean total T4 (P = 0.070) and T3f (P = 0.015), higher T3U (P = 0.013) and TSH (P = 0.020), no difference in free T4, and higher thyroid antithyroglobulin (ATA) (P = 0.033) and antimicrosomal autoantibody (AMA) titres (P = 0.0097). +3 more findings

    Full summary, score breakdown and related studies → Original source

May 1990 7

  1. 1990-05-01

    Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein

    ✓ Peer-reviewed Down syndrome and Alzheimer's Science (New York, N.Y.)

    Key finding: Because PN-II/APP is a potent protease inhibitor and possesses growth factor activity, these results implicate PN-II/APP in wound repair.

    Full summary, score breakdown and related studies → Original source

  2. 1990-05-01

    The aging of America. Impact on health care costs

    ✓ Peer-reviewed Health systems and care delivery JAMA

    Key finding: Without major changes in the health of our older population, these health care costs will escalate enormously, in large part as a result of the projected growth of the "oldest old," those aged 85 years and above.

    Full summary, score breakdown and related studies → Original source

  3. 1990-05-01

    A metaanalysis of controlled trials of neuroleptic treatment in dementia

    ✓ Peer-reviewed Clinical trials Journal of the American Geriatrics Society

    Key finding: Prior qualitative literature reviews about the use of neuroleptics in dementia suggest that they are "modestly effective" in treating agitation and that no single neuroleptic is better than another. +3 more findings

    Full summary, score breakdown and related studies → Original source

  4. 1990-05-01

    Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

    ✓ Peer-reviewed Brain tissue and pathology Annals of Neurology

    Ultrastructural studies of biopsied cortical tissue from the right frontal lobe of 8 patients with mild to moderate Alzheimer's disease (AD) revealed that the number of synapses in lamina III of Brodmann's area 9 was significantly decreased when compared with the number in age-matched control brains (n = 9; postmortem time, less than 13 hours).

    Full summary, score breakdown and related studies → Original source

  5. 1990-05-01

    Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain

    ✓ Peer-reviewed Risk genes beyond APOE Proceedings of the National Academy of Sciences of the United States of America

    Key finding: The proteases that may be involved in this process have not yet been identified. +3 more findings

    Full summary, score breakdown and related studies → Original source

  6. 1990-05-01

    Production and characterization of a monospecific antiserum (A128) to disaggregated Alzheimer paired helical filaments

    ✓ Peer-reviewed Down syndrome and Alzheimer's The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society

    Key finding: We further demonstrated the specificity of this antiserum by electron microscopic immunohistochemistry, gel diffusion analysis, and immunoblotting.

    Full summary, score breakdown and related studies → Original source

  7. 1990-05-01

    The occult aftermath of boxing

    ✓ Peer-reviewed Risk factors Journal of neurology, neurosurgery, and psychiatry

    Key finding: We found that all DP cases with substantial tangle formation showed evidence of extensive beta-protein immunoreactive deposits (plaques). +2 more findings

    Full summary, score breakdown and related studies → Original source

April 1990 6

  1. 1990-04 month only

    Components of burden: interventive implications

    ✓ Peer-reviewed Costs and economics The Gerontologist

    Key finding: Significant relationships between predictor variables and burden components suggest that global scores and measures of burden do not identify specific problem areas relative to the various components of burden.

    Full summary, score breakdown and related studies → Original source

  2. 1990-04-01

    Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing

    ✓ Peer-reviewed Risk genes beyond APOE Science (New York, N.Y.)

    Key finding: This suggests that an intact amyloidogenic beta/A4 fragment is not generated during normal APP catabolism. +1 more finding

    Full summary, score breakdown and related studies → Original source

  3. 1990-04-01

    Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: evidence for a neuronal origin

    ✓ Peer-reviewed Risk genes beyond APOE Brain research

    Key finding: In control and Alzheimer brains, cathepsin immunoreactivity within cells was localized to lysosome-related structures, which were particularly abundant in neuronal perikarya. +3 more findings

    Full summary, score breakdown and related studies → Original source

  4. 1990-04-01

    Red cell superoxide dismutase, glutathione peroxidase and catalase in Down syndrome patients with and without manifestations of Alzheimer disease

    ✓ Peer-reviewed Down syndrome and Alzheimer's American journal of medical genetics

    Key finding: Cu,Zn superoxide dismutase (SOD-1) and glutathione peroxidase (GSHPx) activities were significantly elevated (1.39-fold and 1.24-fold, respectively) in DS individuals without AD. +3 more findings

    Full summary, score breakdown and related studies → Original source

  5. 1990-04-01

    Prevalence of clinically diagnosed Alzheimer's disease and other dementing disorders: a door-to-door survey in Appignano, Macerata Province, Italy

    ✓ Peer-reviewed Disparities Neurology

    Key finding: We found 48 patients affected by dementia, yielding a crude prevalence ratio (cases per 100 population over age 59) of 6.2; prevalence ratios were 2.6 for Alzheimer's disease, 2.2 for multi-infarct dementia, 0.8 for mixed dementia, 0.4 for secondary dementia, and 0.3 for unspecified dementia. +1 more finding

    Full summary, score breakdown and related studies → Original source

  6. 1990-04-01

    The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education

    ✓ Peer-reviewed Getting a diagnosis Annals of neurology

    Key finding: These findings indicate that the prevalence of dementia in Shanghai is very much higher than figures published earlier for China and Japan, and at the lower part of the range of values reported for community residents in the United States and other Western countries, but less than half of that reported in the recently published survey of the elderly in East Boston. +1 more finding

    Full summary, score breakdown and related studies → Original source

March 1990 10

  1. 1990-03-01

    A new mitochondrial disease associated with mitochondrial DNA heteroplasmy

    ✓ Peer-reviewed Disease mechanisms American journal of human genetics

    Key finding: Sequence analysis showed that this was due to a point mutation at nucleotide 8993, resulting in an amino acid change from a highly conserved leucine to arginine in subunit 6 of mitochondrial H(+)-ATPase.

    Full summary, score breakdown and related studies → Original source

  2. 1990-03-01

    Alterations in the circadian rest-activity rhythm in aging and Alzheimer's disease

    ✓ Peer-reviewed Risk factors Biological psychiatry

    Key finding: Comparison of old controls versus AD patients revealed that (1) rest-activity rhythm was markedly disturbed in many of the AD patients and tended to be correlated with the severity of the dementia; (2) disturbances were most pronounced in subjects using sedating drugs; (3) disturbances in the latter group did not result from medication as no differences were found in the rest-activity patterns before and after administration of sedating drugs; (4) negative findings reported in the literature concerning circadian disturbances in AD may well have resulted from selection criteria that excluded the group of patients with the most severely affected rest-activity rhythm; and (5) rest-activity monitors offer a practical and fruitful approach for the study of circadian rhythms in humans.

    Full summary, score breakdown and related studies → Original source

  3. 1990-03-01

    Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

    ✓ Peer-reviewed Genetics Journal of Lipid Research

    Key finding: We have used restriction isotyping (restriction enzyme isoform genotyping) for rapid typing of common apolipoprotein E isoforms (E2, E3, E4). +4 more findings

    Full summary, score breakdown and related studies → Original source

  4. 1990-03-01

    Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini-Mental State Examination

    ✓ Peer-reviewed Cognitive tests and assessment Archives of neurology

    Key finding: We reevaluated the usefulness of the MMSE by studying 85 patients with clinically definite MS who also received an extensive battery of neuropsychological tests. +3 more findings

    Full summary, score breakdown and related studies → Original source

  5. 1990-03-01

    Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques

    ✓ Peer-reviewed Risk genes beyond APOE Proceedings of the National Academy of Sciences of the United States of America

    Key finding: We localized distinct beta-APP domains, including the beta-amyloid protein or A4 region, within the SPs of 13 end-stage Alzheimer disease (AD) and 13 age-matched control samples of hippocampus and entorhinal cortex. +3 more findings

    Full summary, score breakdown and related studies → Original source

  6. 1990-03-01

    The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway

    ✓ Peer-reviewed Risk genes beyond APOE The Journal of biological chemistry

    Key finding: A fourth beta APP form of 563 amino acids does not contain the beta-peptide region. +3 more findings

    Full summary, score breakdown and related studies → Original source

  7. 1990-03-01

    Growth properties and in vitro life span of Alzheimer disease and Down syndrome fibroblasts. A blind study

    ✓ Peer-reviewed Down syndrome and Alzheimer's Mechanisms of ageing and development

    Key finding: Two growth characteristics were examined quantitatively: (i) the actual in vitro replicating life span was determined by counting the number of cells plated the previous week at 500,000 cells/flask (cumulative population doublings); and (ii) the growth potential was examined by a colony size distribution assay. +4 more findings

    Full summary, score breakdown and related studies → Original source

  8. 1990-03-01

    Regional cerebral glucose metabolism is normal in young adults with Down syndrome

    ✓ Peer-reviewed Down syndrome and Alzheimer's Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

    Key finding: Global gray CMRglc equaled 8.76 +/- 0.76 mg/100 g/min (mean +/- SD) in the DS group as compared with 8.74 +/- 1.19 mg/100 g/min in the control group (p greater than 0.05). +2 more findings

    Full summary, score breakdown and related studies → Original source

  9. 1990-03-01

    Defective gallium-transferrin binding in Alzheimer disease and Down syndrome: possible mechanism for accumulation of aluminium in brain

    ✓ Peer-reviewed Down syndrome and Alzheimer's Lancet (London, England)

    Key finding: Gallium-transferrin binding was significantly lower in the Alzheimer (mean [SEM] 7.9 [1.1]%) and Down syndrome groups (6.9 [0.7]%) than in the controls (17.1 [1.6]%), whereas stroke dementia and haemodialysis patients had normal binding.

    Full summary, score breakdown and related studies → Original source

  10. 1990-03-01

    The natural history of dementia in Down's syndrome

    ✓ Peer-reviewed Digital health tools Archives of neurology

    Key finding: Neuropathologically, Alzheimer-type abnormalities were demonstrated in 9 patients, both demented and nondemented, and combined Alzheimer-type abnormalities with infarctions were demonstrated in 1 patient. +1 more finding

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →